Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent

Showing results (821-830 of 1,192) with videos related to

Pageof 120
Sort By:
Mayo Clinic Proceedings|January 17, 2003
Review of 1027 patients with newly diagnosed multiple myelomaRobert A Kyle, Morie A Gertz, Thomas E Witzig, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Blood|November 3, 2007
Improved survival in multiple myeloma and the impact of novel therapiesShaji K Kumar, S Vincent Rajkumar, Angela Dispenzieri, et al.
Blood Cancer Journal|March 18, 2020
The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasiasLinda B Baughn, Zhuo Li, Kathryn Pearce, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trialDaniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Leukemia & Lymphoma|April 11, 2015
Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and bothLadan Zand, Samih H Nasr, Morie A Gertz, et al.
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
Nature Medicine|November 17, 2009
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtinShu-ichi Okamoto, Mahmoud A Pouladi, Maria Talantova, et al.
Leukemia|September 12, 2018
Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristicsAlyssa I Clay-Gilmour, Shaji Kumar, S Vincent Rajkumar, et al.
Pageof 120

Showing results (821-830 of 1,192) with videos related to

Sort By:
Pageof 120
Mayo Clinic Proceedings|January 17, 2003
Review of 1027 patients with newly diagnosed multiple myelomaRobert A Kyle, Morie A Gertz, Thomas E Witzig, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Blood|November 3, 2007
Improved survival in multiple myeloma and the impact of novel therapiesShaji K Kumar, S Vincent Rajkumar, Angela Dispenzieri, et al.
Blood Cancer Journal|March 18, 2020
The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasiasLinda B Baughn, Zhuo Li, Kathryn Pearce, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trialDaniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Leukemia & Lymphoma|April 11, 2015
Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and bothLadan Zand, Samih H Nasr, Morie A Gertz, et al.
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
Nature Medicine|November 17, 2009
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtinShu-ichi Okamoto, Mahmoud A Pouladi, Maria Talantova, et al.
Leukemia|September 12, 2018
Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristicsAlyssa I Clay-Gilmour, Shaji Kumar, S Vincent Rajkumar, et al.
Pageof 120